Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Nivolumab, Nenocorilant 200 Mg, Nenocorilant 300 Mg, Nenocorilant 400 Mg, Cort125236
Neoplasms
Phase I/II
Recruiting
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Dec 01, 2025
―
Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
Healthy
Phase I
Active Not Recruiting
Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
Nov 07, 2025
―
Miricorilant
Nonalcoholic Steatohepatitis (Nash), Metabolic Dysfunction-Associated Steatohepatitis (Mash), Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld), Non-Alcoholic Fatty Liver Disease (Nafld)
Phase I
Recruiting
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Apr 21, 2025
Dazucorilant
Hepatic Impairment
Phase I
Completed
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Apr 08, 2025
―
Nab-Paclitaxel 80 Mg/M^2, Relacorilant 150 Mg Once Daily, Bevacizumab 10 Mg/Kg
Peritoneal Neoplasms, Ovarian Cancer, Fallopian Tube Cancer
Phase II
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Apr 01, 2025
―
Itraconazole, Dazucorilant
Healthy Adults
Phase I
Completed
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
Jul 03, 2024
―
Miricorilant
Nonalcoholic Steatohepatitis, Metabolic Dysfunction-associated Steatohepatitis
Phase II
Active Not Recruiting
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Oct 23, 2023
―
Cort125134 150 Mg, Cort125134 250 Mg, Cort125134 Dose To Be Determined
Healthy
Phase I
Completed
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
Oct 17, 2023
―
Cort125134
Healthy
Phase I
Completed
A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
Oct 17, 2023
―
Relacorilant
Hepatic Impairment
Phase I
Completed
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Oct 17, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Corcept Therapeutics Inc. (CORT) have in its pipeline
CORT is currently developing the following drugs: Nivolumab, Nenocorilant 200 Mg, Nenocorilant 300 Mg, Nenocorilant 400 Mg, Cort125236, Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D, Miricorilant. These drug candidates are in various stages of clinical development as the company works toward FDA approval.